Hematologic Malignancies Demystified – Houston
Symposium
Symposium

Hematologic Malignancies Demystified – Houston

A Critical Appraisal of Data From 2019

Not a member of My prIME? Join now for instant access.

Explore the options in hematologic malignancies and disorders with this live meeting. Stay informed on new data with established agents and gain insight into the use of novel agents in your practice. Expert faculty will focus on updates from recent congresses and the latest clinically relevant data.

Date and Location

Saturday, February 1, 2020
Time: 8:00 AM – 4:00 PM

Hyatt Regency Houston Galleria
2626 Sage Road
Houston, Texas, United States 77056
General Session: Regency AB

Date/Time

Date/Time

Saturday, February 1, 2020

Location

Location

Houston, Texas, United States

CME

CME

6.25 AMA PRA Category 1 Credit(s)™

CE

CE

6.25 Contact Hours

7:00 AM Registration and continental breakfast
8:00 AM Welcome and introduction
8:15 AM Frontline multiple myeloma
8:45 AM Relapsed/refractory multiple myeloma
9:15 AM Myeloproliferative neoplasms
9:45 AM Oncology Guru™ hematology quiz
9:55 AM Break
10:25 AM Myelodysplastic syndromes
10:55 AM Acute myeloid leukemia
11:25 AM Acute lymphoblastic leukemia
11:55 AM Chronic myeloid leukemia
12:25 PM Oncology Guru™ hematology quiz
12:35 PM Lunch
1:35 PM Chronic lymphocytic leukemia
2:05 PM Hodgkin lymphoma and indolent non-Hodgkin lymphoma
2:35 PM Aggressive non-Hodgkin lymphoma
3:05 PM Benign hematology
3:35 PM Discussion and concluding remarks
3:50 PM Oncology Guru™ hematology quiz and MOC questions
4:00 PM Adjourn

Please note that specific presentation times are subject to change.

    Course Director

  • Hagop M. Kantarjian, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Faculty

  • Kenneth Anderson, MDHarvard Medical School and Dana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Jorge Cortes, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Courtney DiNardo, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Guillermo Garcia-Manero, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Elias Jabbour, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Sagar Lonial, MDWinship Cancer Institute
    Emory University
    Atlanta, Georgia, United States
  • Stephan Moll, MDUniversity of North Carolina, School of Medicine
    Chapel Hill, North Carolina, United States
  • Susan O'Brien, MDUC Irvine Health
    Chao Family Comprehensive Cancer Center
    Orange, California, United States
  • Ayalew Tefferi, MDMayo Clinic College of Medicine
    Rochester, Minnesota, United States
  • Julie Vose, MD, MBAUniversity of Nebraska Medical Center
    Omaha, Nebraska, United States
  • Anas Younes, MDMemorial Sloan-Kettering Cancer Center
    New York, New York, United States

This educational activity is specifically designed for hematologists/oncologists, nurses, nurse practitioners, and other healthcare professionals who are involved or interested in the management of patients with hematologic malignancies and disorders.

Upon completion of this activity, physicians will demonstrate:

  • Increased knowledge regarding the
    • Emerging clinical trial data investigating established and novel treatments for hematologic malignancies and disorders
    • Methods to assess and monitor treatment response in patients with hematologic malignancies or disorders
    • Treatment-related side effects in patients with hematologic malignancies or disorders
  • Greater competence related to
    • Individualizing treatment in patients with hematologic malignancies or disorders

Upon completion of this activity, nurses will demonstrate:

  • Increased knowledge regarding the
    • Emerging clinical trial data investigating established and novel treatments for hematologic malignancies and disorders
    • Treatment-related side effects in patients with hematologic malignancies or disorders

Date and Location

Saturday, February 1, 2020
Time: 8:00 AM – 4:00 PM

Hyatt Regency Houston Galleria
2626 Sage Road
Houston, Texas, United States 77056
General Session: Regency AB

Supported by independent educational grants from AstraZeneca Pharmaceuticals LP, Celgene Corporation, Jazz Pharmaceuticals, and Seattle Genetics, Inc.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and prIME Oncology. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Awarded 6.25 contact hour(s) of continuing nursing education for RNs and APNs.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Provider

This activity is jointly provided by Medscape, LLC and prIME Oncology.

Sunshine/EFPIA Statement

Medscape, LLC and prIME Oncology comply with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.